Scripps Cardiovascular Atherosclerosis Prediction, Prevention and Management 2023

Course Overview

Scripps Cardiovascular Atherosclerosis Prediction, Prevention and Management 2023 Despite notable advances in management, atherosclerotic cardiovascular disease (ASCVD) and its major clinical manifestations remains a leading cause of both morbidity and mortality worldwide. In the United States alone, ASCVD is the leading cause of death in most racial and ethnic populations and is estimated to cost more than $200 billion per year due to medications, healthcare service utilization, and productivity losses.

Many of these human and economic costs are largely attributable to poor implementation of prevention strategies in adults and failure to control ASCVD risk factors using available medications and lifestyle interventions. The Scripps Cardiovascular Atherosclerosis conference is designed to assist clinicians in the prevention, diagnosis, treatment, and ongoing management of ASCVD among patients in their clinical practices as well as to promote increased awareness of prudent lifestyle and dietary choices to improve patient outcomes.

Description

+ Include: 13 videos + 1 pdf, size: 2.36 GB

+ Target Audience: cardiologist, endocrinologists, internists

 Topics:

• brochure_lipids23_compressed.pdf
• Advanced Hypertension Management.mp4
• Bio-Identical Hormones and Testosterone Supplementation.mp4
• Evaluate Horrible Cholesterol, Lipoprotein A Prevalence, Impact, and Novel Therapeutics.mp4
• Genetic Testing for Familial Hypercholesterolemia When to Test, Whom to Test.mp4
• New Concepts in Dyslipidemia Dispelling 10 Truths About Lipids.mp4
• Non-HDL Targets for Risk Reduction.mp4
• Nonalcoholic Fatty Liver Disease and Its Contribution to CV Disease.mp4
• Obesity and Diabetic Pharmacotherapy Are You Ready for GLP-1 Agonists.mp4
• Panel Discussion Q&A 1.mp4
• Panel Discussion Q&A 2.mp4
• Panel Discussion Q&A 3.mp4
• Panel Discussion Q&A 4.mp4
• Supplements in Primary and Secondary Prevention of ASCVD.mp4